

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

Non-Preferred Inhaled Corticosteroid (ICS)/Long-Acting Beta-2 Agonist (LABA) Combination Agents

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medication	Comments	Quantity Limit
fluticasone/salmeterol (generic AirDuo RespiClick)	Preferred	May be subject to quantity limit
Wixela Inhub (fluticasone/salmeterol)		
Authorized Generic Advair Diskus (fluticasone/salmeterol)		
Authorized Generic Symbicort (budesonide/formoterol)		
AirDuo RespiClick (fluticasone/salmeterol)	Non-Preferred	
AirDuo Digihaler (fluticasone/salmeterol)		
Advair Diskus (fluticasone/salmeterol)		
Advair HFA (fluticasone/salmeterol)		
Breo Ellipta (fluticasone/vilanterol)		
Dulera (mometasone/formoterol)		
Symbicort (budesonide/formoterol)		

APPROVAL CRITERIA

- I. Requests for a non-preferred ICS/LABA combination agent may be approved if the following criteria are met:

CRX-ALL-0573-20

PAGE 1 of 2 08/01/2020

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

- A. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response or intolerance to one preferred ICS/LABA combination agent [preferred agents are fluticasone/salmeterol (generic AirDuo Respiclick), Wixela Inhub (fluticasone/salmeterol), Authorized Generic Advair Diskus (fluticasone/salmeterol), Authorized Generic Symbicort (budesonide/formoterol)];

Key References:

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: October 3, 2019.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Fanta CH. An overview of asthma management. Last updated: October 5, 2017. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. Accessed: September 30, 2019.
4. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2018. Available from: <http://ginasthma.org/gina-reports/>. Accessed on: December 21, 2018.
5. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019. Available from: Available from: <http://goldcopd.org>. Accessed on: January 3, 2019.
6. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.